HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a licensing agreement to integrate HealthVerity's extensive real-world data into its platforms. In the same week, Recursion reported ...

PHILADELPHIA - Recursion (NASDAQ: RXRX), a clinical stage TechBio company with a market capitalization of $2.27 billion, has entered into a licensing agreement with HealthVerity to utilize its ...

What programming languages like R and Python are to data science, packages within BioNeMo are hoping to be the same for drug development. Nvidia says that cloud APIs are being unveiled on the ...

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a ...

In other recent news, Recursion Pharmaceuticals reported fourth-quarter revenues of $4.5 million, which represented a 57% year-over-year decrease and fell short of Cowen’s projection of $19 million.

Search for Symbols, analysts, keywords Log in HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data Apr. 16, 2025 8:30 AM ETRecursion Pharmaceuticals, Inc ...

Company News Published 04/16/2025, 08:48 AM 0 Recursion licenses HealthVerity real-world data for trials RXRX -10.11% ...